Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: Best BioPharma Books of 2019

Diverse Thinking Across Healthcare Writing

Executive Summary

Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.

 

You may also be interested in...



AstraZeneca Returns To Growth, But Coronavirus Likely To Hit China Revenues

With a long turnaround process now complete, AstraZeneca could hit double digit growth in 2020, thanks to existing products and new approvals such as roxadustat. 

AlloVir Gains PRIME Status For Anti-Virus T-Cell Therapy

Joining the ElevateBio stable last May, the company has now gained priority status in the US and Europe for its novel therapy for viral infections in stem cell transplant patients.

Novartis And UK Launch Partnership On Groundbreaking Cardiovascular Prevention Trial

Partnership includes provision for fast-tracked uptake of inclisiran in England, if NICE finds it cost effective.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141392

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel